Evaluation of disulfiram plus arsenic trioxide in patients with metastatic melanoma and at least one prior systemic therapy (phase 1b).

Trial Profile

Evaluation of disulfiram plus arsenic trioxide in patients with metastatic melanoma and at least one prior systemic therapy (phase 1b).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Arsenic trioxide (Primary) ; Disulfiram
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Planned end date changed from 1 Dec 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 31 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top